Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14509623 | 0.82 | ADORA3 (0.34) | IDH1 | |
| SCHEMBL12416262 | 0.81 | MMP9 (0.32) | — | |
| SCHEMBL13245239 | 0.80 | HTR2A (0.33) | TNKS2 | |
| SCHEMBL14408314 | 0.79 | TNKS2 (0.31) | IDH1TNKS2 | |
| SCHEMBL12416269 | 0.78 | CYP17A1 (0.30) | — | |
| SCHEMBL12416271 | 0.78 | ADORA3 (0.34) | — | |
| SCHEMBL14416156 | 0.77 | — | — | |
| SCHEMBL8290137 | 0.75 | TNKS2 (0.33) | IDH1TNKS2 | |
| SCHEMBL12416319 | 0.74 | P2RX3 (0.31) | P2RX3 | |
| SCHEMBL12416315 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130177531-A1 | Inhibitors of Serine Proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-11 | — | — | US | disclosed |
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-14 | — | — | US | disclosed |
| US-20070105781-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171175-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | IDH1 2944/4885P2RX3 4765/4885TNKS2 2419/4885 |
| US-20140056847-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SERPINB1, PRSS3 | IDH1 2944/4885P2RX3 4765/4885TNKS2 2419/4885 |
| US-20130177531-A1 | Inhibitors of Serine Proteases | PRSS1, SERPINB1, PRSS3 | IDH1 2944/4885P2RX3 4765/4885TNKS2 2419/4885 |
| US-20070105781-A1 | Inhibitors of serine proteases | PRSS1, SERPINB1, PRSS3 | IDH1 2926/4885P2RX3 4779/4885TNKS2 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.